Drugs / Piclidenoson
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 210 trials | ||||||
| Phase 2 | NCT07410455 | Jun 2026 → Aug 2027 expected | oculocerebrorenal syndrome | Can-Fite BioPharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04333472 | Jan 2021 → Mar 2022 | COVID-19 | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT01905124 | Jan → Sep 2019 | intermediate uveitis, posterior uveitis | Can-Fite BioPharma | Withdrawn | No outcome recorded |
| Phase 2 | NCT00837291 | Nov → Dec 2018 | osteoarthritis, knee | Can-Fite BioPharma | Withdrawn | No outcome recorded |
| Phase 2 | NCT01034306 | Oct 2010 → Dec 2013 | rheumatoid arthritis | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT01033422 | Oct 2010 → Dec 2016 | glaucoma, ocular hypertension | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00556894 | Feb 2008 → Mar 2009 | rheumatoid arthritis | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00428974 | Jun 2007 → Sep 2009 | psoriasis | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00349466 | Jan 2007 → May 2009 | dry eye syndrome | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2 | NCT00280917 | Jun 2006 → Apr 2007 | rheumatoid arthritis | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01265667 | Jul 2011 → Mar 2015 | psoriasis | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06643260 | Jun 2025 → Dec 2027 expected | psoriasis | Can-Fite BioPharma | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03168256 | Sep 2018 → Jan 2022 | psoriasis | Can-Fite BioPharma | Completed | No outcome recorded |
| Phase 3 | NCT02647762 | Oct 2017 → Nov 2020 | rheumatoid arthritis | Can-Fite BioPharma | Terminated | No outcome recorded |
| Phase 3 | NCT01235234 | Jul 2011 → Nov 2013 | dry eye syndrome | Can-Fite BioPharma | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piclidenoson | “We investigated the efficacy/safety of piclidenoson (CF101), an orally bioavailable A3AR agonist that inhibits IL-17 and IL-23 production in keratinocytes, in...” PMID 38279575 ↗ Jan 2024 |
| Known as | ALB-7208 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989873 ↗ |
| Known as | CF101 | “We investigated the efficacy/safety of piclidenoson (CF101), an orally bioavailable A3AR agonist that inhibits IL-17 and IL-23 production in keratinocytes, in...” PMID 38279575 ↗ Jan 202413“A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Subjects With Moderate-to-Severe...” NCT06643260 ↗ “Piclidenoson (CF101) open-label treated patients” NCT07410455 ↗ |
| Known as | IB-MECA | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989873 ↗ |
| Action | Activate | “A(3) adenosine receptor agonist” PMID 20304499 ↗ Mar 20101“Adenosine A3 receptor agonist” CHEMBL3989873 ↗ |
| Modality | Small molecule | — CHEMBL3989873 ↗ |
| Route | Oral | “CF101 0.1 mg, CF101 1 mg, CF101 4 mg, or placebo given orally q12h for 12 weeks” NCT00280917 ↗ |
| Target | ADORA3 | “Adenosine A3 receptor agonist” CHEMBL3989873 ↗ |